Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Share:
Related MRK
Merck Announces New Data on Breadth of KEYTRUDA at ASCO: Anti-Tumor Activity Now Shown in 13 Different Tumor Types
Expert Explains How To Play Merck In 2 Charts
Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog (Zacks)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Latest Ratings for MRK

DateFirmActionFromTo
May 2015JefferiesMaintainsHold
Apr 2015Deutsche BankMaintainsHold
Mar 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: News Upgrades Price Target Markets Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...